# A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

> **NCT05167825** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 7 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Macitentan

## Key facts

- **NCT ID:** NCT05167825
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-14
- **Primary completion:** 2024-08-23
- **Final completion:** 2025-03-05
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167825, "A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05167825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*